Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Kimberly Maersk-MollerChief Commercial Officer | Mimedx GroupMDXG | Open-market sale | 25/11/06 | 25/11/10 | 58,300 sh | $7.42 | $432,586 | −19.7% |
Mimedx GroupMDXG | Open-market buy | 25/05/02 | 25/05/05 | 200,000 sh | $6.34 | $1,268,000 | +60.7% | |
Kimberly Maersk-MollerChief Commercial Officer | Mimedx GroupMDXG | Open-market sale | 25/03/17 | 25/03/20 | 1,759 sh | $8.04 | $14,142.36 | −0.6% |
Mimedx GroupMDXG | Open-market sale | 25/03/13 | 25/03/14 | 54,596 sh2 trades | $7.89avg. | $430,762.44 | −11.0% | |
Kimberly Maersk-MollerChief Commercial Officer | Mimedx GroupMDXG | Open-market sale | 25/03/13 | 25/03/14 | 4,106 sh | $7.89 | $32,396.34 | −1.3% |
William Frank Hulse IVGeneral Counsel and CAO | Mimedx GroupMDXG | Open-market sale | 25/03/10 | 25/03/12 | 81,446 sh | $7.80 | $635,278.8 | −14.1% |
Kimberly Maersk-MollerChief Commercial Officer | Mimedx GroupMDXG | Open-market sale | 25/02/28 | 25/03/05 | 2,111 sh | $8.41 | $17,753.51 | −0.8% |
Mimedx GroupMDXG | Open-market sale | 25/02/13 | 25/02/18 | 61,420 sh | $8.28 | $508,557.6 | −13.2% | |
William Frank Hulse IVGeneral Counsel and CAO | Mimedx GroupMDXG | Open-market sale | 24/03/13 | 24/03/15 | 20,381 sh | $7.95 | $162,028.95 | −4.1% |
Mimedx GroupMDXG | Open-market sale | 24/02/16–24/02/20 | 24/02/21 | 30,764 sh2 trades | $8.04avg. | $247,349.22 | −7.1% | |
Mimedx GroupMDXG | Open-market sale | 24/02/14–24/02/15 | 24/02/16 | 31,043 sh2 trades | $8.04avg. | $249,731.23 | −6.7% | |
Rice DougCFO | Mimedx GroupMDXG | Open-market buy | 23/11/21 | 23/11/22 | 5,000 sh | $7.16 | $35,800 | +5.1% |
Mimedx GroupMDXG | Open-market buy | 23/06/22–23/06/23 | 23/06/26 | 100,000 sh2 trades | $6.40avg. | $640,144.25 | No record | |
Mimedx GroupMDXG | Open-market sale | 23/05/15–23/05/16 | 23/05/17 | 13,972 sh2 trades | $6.00avg. | $83,854.8 | −4.2% | |
Mimedx GroupMDXG | Open-market sale | 23/05/10 | 23/05/12 | 5,976 sh | $5.93 | $35,437.68 | −0.9% | |
Robert Benjamin SteinPresident, Regenerative Med | Mimedx GroupMDXG | Open-market sale | 23/05/10 | 23/05/12 | 5,869 sh | $5.93 | $34,803.17 | −1.7% |
William Frank Hulse IVGeneral Counsel and CAO | Mimedx GroupMDXG | Open-market sale | 23/05/10 | 23/05/12 | 5,870 sh | $5.93 | $34,809.1 | −1.3% |
William Lawrence PhelanChief Accounting Officer | Mimedx GroupMDXG | Open-market sale | 23/05/10 | 23/05/12 | 1,595 sh | $5.93 | $9,458.35 | −0.9% |
Robert Benjamin SteinPresident, Regenerative Med | Mimedx GroupMDXG | Open-market sale | 23/05/04 | 23/05/09 | 51,756 sh | $5.34 | $276,377.04 | −13.3% |
William Lawrence PhelanChief Accounting Officer | Mimedx GroupMDXG | Open-market sale | 23/05/02 | 23/05/03 | 5,200 sh | $3.80 | $19,760 | −2.7% |